0001104659-26-081586.txt : 20260708 0001104659-26-081586.hdr.sgml : 20260708 20260708083116 ACCESSION NUMBER: 0001104659-26-081586 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20260701 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260708 DATE AS OF CHANGE: 20260708 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GMR Solutions Inc. CENTRAL INDEX KEY: 0001898718 STANDARD INDUSTRIAL CLASSIFICATION: TRANSPORTATION SERVICES [4700] ORGANIZATION NAME: 01 Energy & Transportation EIN: 473615769 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-43289 FILM NUMBER: 261160824 BUSINESS ADDRESS: STREET 1: 4400 HWY 121 STREET 2: SUITE 700 CITY: LEWISVILLE STATE: TX ZIP: 75056 BUSINESS PHONE: 877-244-4890 MAIL ADDRESS: STREET 1: 4400 HWY 121 STREET 2: SUITE 700 CITY: LEWISVILLE STATE: TX ZIP: 75056 FORMER COMPANY: FORMER CONFORMED NAME: GMR Buyer Corp. DATE OF NAME CHANGE: 20211213 8-K 1 tm2619986d1_8k.htm FORM 8-K
false 0001898718 0001898718 2026-07-01 2026-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 1, 2026

 

 

 

GMR Solutions Inc.

 

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 001-43289 47-3615769

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

4400 Hwy 121, Suite 700,
Lewisville, TX 75056
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (972) 459-4919

 

Not applicable
(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of each exchange
on which registered

Class A common stock, par value $0.0001 per share GMRS The New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Directors; Director Compensation

 

On July 1, 2026, each of Dr. Amar Desai and Ellen Zane were appointed to the Board of Directors (the “Board”) of GMR Solutions Inc. (the “Company”), effective immediately. The Board has determined that each of Dr. Desai and Ms. Zane qualifies as “independent” in accordance with the rules of the New York Stock Exchange. The Company’s Amended and Restated Certificate of Incorporation provides for a classified Board. Ms. Zane will serve as a Class II director with a term expiring at the Company’s 2028 annual meeting of stockholders and Dr. Desai will serve as a Class III director with a term expiring at the Company’s 2029 annual meeting of stockholders.

 

Dr. Desai previously served as the President of Optum Integrated Care at Optum, a national, comprehensive and patient-centered care organization, from August 2025 to March 2026. Prior to that, Dr. Desai served as Chief Executive Officer, Optum Health at UnitedHealth Group from July 2023 through August 2025. Dr. Desai first joined Optum in 2019 when he served as President, HealthCare Partners, and later became President and CEO of Optum Pacific West and Optum California until 2022. Prior to rejoining Optum, he served as President, Health Care Delivery of CVS Health from 2022 to 2023. Previously, Dr. Desai served as a senior executive at DaVita, a global leader in dialysis care, from 2016 to 2019 and from 2010 to 2014, and as Chief Executive Officer of University of Southern California (“USC”) Care, the faculty practice plan, community network and ambulatory health system of Keck Medicine of USC, from 2014 to 2016. Earlier in his career, Dr. Desai served as an engagement manager at McKinsey & Company. Dr. Desai earned his bachelor’s and medical degrees from Brown University, and his master’s in public health from Harvard T.H. Chan School of Public Health. He has previously served as associate clinical professor of medicine at Keck School of Medicine at USC and held faculty appointments at Stanford School of Medicine and the David Geffen School of Medicine at UCLA.

 

Ms. Zane is CEO Emeritus at Tufts Medical Center, Founding Chair at Tufts Medicine and an Adjunct Assistant Professor of Health Policy and Management at Harvard T.H. Chan School of Public Health. Ms. Zane previously served as President and Chief Executive Officer of Tufts Medical Center from 2004 to 2011 when she retired from this role. Prior to this, Ms. Zane served as Network President for Mass General Brigham (formerly Partners Healthcare System), a physician/hospital network sponsored by the Harvard-affiliated Massachusetts General Hospital and Brigham and Women’s Hospital. Ms. Zane also previously served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane currently is a director of several privately held companies, including Perspectum Solutions, a health solutions and imaging company, Savista, a healthcare revenue cycle management company and AgNovos Healthcare, LLC, a medical device company focused on bone health. Ms. Zane is currently a director of Boston Scientific, Haemonetics Corporation and Synchrony Financial and previously served as a director of Azenta, Inc., Century Capital Management, Parexel International Corporation, Lincare Holdings Inc., Press Ganey Holdings and Fiduciary Trust Company. Ms. Zane has received Honorary Degrees from Curry College, Stonehill College, Bentley University, University of Massachusetts-Dartmouth and the Mass General Brigham University of Health Professions. Ms. Zane received an MA in audiology and speech-language pathology from Catholic University of America and a BA from George Washington University.

 

There are no arrangements or understandings between each of Dr. Desai and Ms. Zane and any other person pursuant to which he or she, as applicable, was appointed as a director of the Company. There are no transactions in which either Dr. Desai or Ms. Zane has an interest requiring disclosure under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

 

Dr. Desai will also serve on the Nominating, Corporate Governance and Compliance Committee of the Board and Ms. Zane will serve as chair of the Human Capital and Compensation Committee of the Board.

 

In connection with their appointment to the Board, on July 1, 2026, the Company granted to each of Dr. Desai and Ms. Zane an award of 9,972 restricted stock units (“RSUs”) under the GMR Solutions Inc. 2026 Equity Incentive Plan (the “Plan”), which RSUs will vest on the first anniversary of the date of their appointment (or, if earlier, upon the occurrence of a Change in Control (as defined in the Plan) or a termination due to death or Disability (as defined in the Plan)).

 

Item 7.01 Regulation FD Disclosure.

 

In connection with the foregoing director appointments, the Company issued a press release on July 8, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

2

 

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.		   Description
99.1   Press Release of GMR Solutions Inc. dated July 8, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

3

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

 

  GMR Solutions Inc.
   
Date: July 8, 2026  
  By:

/s/ Thomas Cook

  Name: Thomas Cook
  Title: Executive Vice President, General Counsel and Secretary

 

4

 

 EX-99.1 2 tm2619986d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

GMR Solutions Strengthens Board with Appointments of Healthcare
Leaders Dr. Amar Desai and Ellen Zane

 

Appointments Complete Board with Expertise Spanning Healthcare Transformation, Workforce Leadership, Governance and Value-Based Care

 

Lewisville, Texas (July 8, 2026) — GMR Solutions, Inc. (NYSE: GMRS) (GMR), the nation's leading emergency medical services (EMS) provider, announced the appointments of Dr. Amar Desai and Ellen Zane to its Board of Directors, effective July 1, 2026.

 

The appointments bring decades of leadership experience across healthcare delivery, value-based care, health system operations, human capital management, and corporate governance, further strengthening the Board as GMR advances its long-term strategy as a leading provider of emergency medical services.

 

"The completion of our Board marks an important milestone for GMR as a public company," said GMR Chief Executive Officer and Chairman Nick Loporcaro. "Our directors bring diverse perspectives and deep expertise from organizations that have transformed healthcare delivery, improved patient access and driven operational excellence at scale. We look forward to leveraging their collective insight as we execute our long-term strategy and deliver value for patients, partners, and shareholders."

 

Dr. Amar Desai Brings Deep Expertise in Healthcare Delivery Transformation

 

Dr. Desai is a respected healthcare executive, with a career spanning medicine, public health and executive leadership across integrated healthcare systems, physician organizations and Fortune 100 healthcare companies.

 

Most recently he served as President of Optum Integrated Care, where he helped advance clinical quality, patient outcomes and value-based care strategies. Before that, Dr. Desai was Chief Executive Officer of Optum Health at UnitedHealth Group, overseeing one of the country's largest care delivery organizations serving more than 20 million patients.

 

Throughout his career, Dr. Desai has focused on expanding innovative care models that improve outcomes, enhance the patient experience, and lower the total cost of care. His leadership experience includes senior roles at CVS Health, DaVita, USC Care, and McKinsey & Company.

 

"As healthcare delivery continues to evolve, organizations that can effectively connect patients to the right care at the right time will play an increasingly important role in improving outcomes and strengthening communities," said Dr. Desai. "With innovative programs like 911 Nurse Navigation and rural health transformation solutions, GMR serves a unique and essential role within the healthcare ecosystem, and I look forward to supporting the company's mission and future growth."

 

Dr. Desai will serve on the Board's Nominating, Corporate Governance and Compliance Committee.

 

 

 

 

Ellen Zane Adds Decades of Healthcare Leadership and Governance Experience

 

Zane is CEO Emeritus of Tufts Medical Center and Founding Chair of Tufts Medicine. Widely recognized as an influential healthcare leader, she brings more than four decades of experience leading healthcare organizations through growth, transformation, and operational change.

 

In addition to her distinguished career in academic medicine and health system leadership, Zane currently serves on the boards of Boston Scientific, Haemonetics Corporation and Synchrony Financial, among other organizations and serves as Adjunct Assistant Professor of Health Policy and Management at Harvard T.H. Chan School of Public Health. Her expertise spans organizational leadership, talent strategy, governance, and operational performance.

 

"GMR's clinicians and team members serve a vital role in communities across the country every day," said Zane. "I am honored to join the Board and look forward to helping the company continue investing in its people, supporting its culture and advancing its mission."

 

Zane will serve as Chair of the Board's Human Capital and Compensation Committee.

 

A Board Built for the Future of Healthcare

 

With the addition of Desai and Zane, the GMRS Board includes healthcare and investment leaders such as Timothy Wicks, former Chief Financial Officer of Optum and former Chief Executive Officer of OptumRx; Jan Stern Reed, former Senior Vice President, General Counsel and Corporate Secretary of Walgreens Boots Alliance, Inc.; Johnny Kim, Managing Director on KKR's Health Care industry team; Max Lin, Partner and Head of KKR's Health Care industry team; and GMR Chief Executive Officer and Chairman, Nick Loporcaro.

 

Together, these leaders bring experience that spans nearly every facet of the healthcare ecosystem—from care delivery and health system operations to governance, workforce leadership, finance and value-based care.

 

Their combined expertise reflects GMR's vision for the future of emergency medical services—one in which EMS is increasingly recognized as an essential component of the broader healthcare system.

 

"Healthcare is changing, and GMR is helping lead that transformation," said Loporcaro. "Every day, our clinicians make critical decisions, deliver advanced medical care and support patients during some of the most significant moments of their lives. At the same time, we're increasingly seeing people turn to 911 and emergency services because they don't know where else to go for care. EMS is no longer defined by transportation; it is an essential entry point into the healthcare system and a vital link across the continuum of care.”

 

 

 

 

About Global Medical Response

 

GMR is the nation’s largest provider of emergency medical services (“EMS”), delivering EMS and other essential out-of-hospital care in rural and urban communities that represent more than 60% of the U.S. population. As the only national, fully integrated, air and ground EMS provider, GMR operates in approximately 1,400 counties across the country. A recognized innovator, GMR develops new solutions to meet evolving industry needs and expand access to high-quality care. With roughly 34,000 team members, GMR supports roughly 5.5 million patient encounters annually and performs a critical care intervention every 88 seconds. Its family of solutions includes American Medical Response, Air Evac Lifeteam, REACH Air Medical Services, Guardian Flight, Med-Trans Corporation, and AirMed International.

 

Media Contact:

 

Kirsten Gurmendi
Associate Vice President, Public Relations
media@gmr.net

877.418.2980

 

Investor Contact:

Krister Sorensen

Vice President, Investor Relations

Investor.relations@gmr.net

 

 

 

 EX-101.SCH 3 gmrs-20260701.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 gmrs-20260701_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 gmrs-20260701_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2619986d1_ex99-1img001.jpg GRAPHIC begin 644 tm2619986d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover
Jul. 01, 2026
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 01, 2026
Entity File Number 001-43289
Entity Registrant Name GMR Solutions Inc.
Entity Central Index Key 0001898718
Entity Tax Identification Number 47-3615769
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4400 Hwy 121
Entity Address, Address Line Two Suite 700
Entity Address, City or Town Lewisville
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75056
City Area Code 972
Local Phone Number 459-4919
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol GMRS
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 23 1 false 0 0 false 0 false false R1.htm 00000001 - Document - Cover Sheet http://globalmedicalresponse.com/role/Cover Cover Cover 1 false false All Reports Book All Reports gmrs-20260701.xsd gmrs-20260701_lab.xml gmrs-20260701_pre.xml tm2619986d1_8k.htm http://xbrl.sec.gov/dei/2025 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2619986d1_8k.htm": { "nsprefix": "GMRS", "nsuri": "http://globalmedicalresponse.com/20260701", "dts": { "schema": { "local": [ "gmrs-20260701.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "labelLink": { "local": [ "gmrs-20260701_lab.xml" ] }, "presentationLink": { "local": [ "gmrs-20260701_pre.xml" ] }, "inline": { "local": [ "tm2619986d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 23 }, "report": { "R1": { "role": "http://globalmedicalresponse.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2026-07-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2619986d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-07-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2619986d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://globalmedicalresponse.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-26-081586-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-26-081586-xbrl.zip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end XML 16 tm2619986d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001898718 2026-07-01 2026-07-01 false 0001898718 8-K 2026-07-01 GMR Solutions Inc. DE 001-43289 47-3615769 4400 Hwy 121 Suite 700 Lewisville TX 75056 972 459-4919 false false false false Class A common stock, par value $0.0001 per share GMRS NYSE false